This article explains how the atherogenic index of plasma predicts risk across fifteen common diseases and includes an AIP calculator you can use to see where you stand.
🎧 ▶️ Press the play button below to listen in English.
🇨🇳 中文（简体）
本文将介绍血浆致动脉硬化指数如何预测十五种常见疾病风险，并包含一个可用于计算个人AIP值的计算器。
请按下方的播放按钮收听。
🇪🇸 Spanish (Latinoamérica)
Este artículo explica cómo el índice aterogénico del plasma predice el riesgo de quince enfermedades comunes e incluye una calculadora de AIP para que puedas conocer tu resultado.
Presiona el botón de reproducir para escuchar.
Introduction: A Simple Ratio With Surprisingly Broad Power
Most people are familiar with cholesterol numbers like LDL, HDL, and triglycerides. Fewer people realize that how these numbers relate to each other can sometimes matter more than any single value alone. The Atherogenic Index of Plasma (AIP) is one of those relationships—and it turns out to be far more informative than most clinicians and patients realize.
AIP is calculated from two routine lab values: triglycerides and HDL cholesterol. That’s it. No advanced testing, no special markers, no extra cost. Yet this simple ratio quietly reflects several deep metabolic processes happening beneath the surface—lipoprotein particle size, insulin resistance, inflammation, and vascular stress. In many studies, AIP predicts disease risk even when LDL cholesterol looks “normal.”
What makes AIP especially compelling is its breadth. Research over the past decade has linked elevated AIP not just to heart disease, but to stroke, kidney disease, metabolic dysfunction, vascular calcification, cognitive decline, and even outcomes in acute illness. In other words, AIP behaves less like a narrow lipid marker and more like a global metabolic stress signal.
This matters in a world where cardiometabolic disease is rising despite widespread cholesterol testing and treatment. Many people are told their labs are “fine,” yet still go on to develop diabetes, hypertension, atherosclerosis, or chronic kidney disease. AIP helps explain why. It often rises years before these conditions become clinically obvious.
In this article, we’ll walk through 15 important and sometimes surprising uses of the Atherogenic Index of Plasma, grouped in a way that makes sense clinically and practically. By the end, you’ll understand why this easy-to-calculate number deserves a place alongside blood pressure, glucose, and waist size—and why tracking it can offer insights that standard lipid panels often miss.
II. What Is the Atherogenic Index of Plasma (AIP)?
The Atherogenic Index of Plasma (AIP) is a logarithmic ratio calculated from two values found on a standard lipid panel: triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). It is defined as:
AIP = log₁₀ (Triglycerides ÷ HDL-Cholesterol)
(both values expressed in mmol/L)
At first glance, this may look like just another lipid ratio. In reality, AIP captures something far more important than either triglycerides or HDL alone—it reflects the quality and behavior of circulating lipoproteins, not just their quantity.
High triglycerides and low HDL cholesterol tend to travel together in states of insulin resistance, excess visceral fat, and chronic inflammation. When this happens, LDL particles become smaller, denser, and more atherogenic, even if the total LDL-C number remains within the “normal” range. AIP correlates strongly with the presence of these small dense LDL particles, which are more likely to penetrate the arterial wall, oxidize, and promote plaque formation.
This is why AIP often identifies risk in people who appear metabolically healthy on routine testing. Someone may have:
- LDL-C in the normal range
- Total cholesterol that looks acceptable
- No obvious red flags on a basic lipid report
Yet still have an elevated AIP, signaling hidden cardiometabolic stress.
Another advantage of AIP is its physiologic coherence. Triglycerides rise when the body struggles to handle energy efficiently—particularly after meals—while HDL tends to fall in inflammatory and insulin-resistant states. By combining these two opposing markers into a single index, AIP amplifies clinically meaningful patterns that are easy to miss when each value is viewed in isolation.
In practical terms, AIP acts as a window into lipid metabolism, insulin sensitivity, and vascular health. It does not replace traditional lipid measurements, but it often explains them, especially when clinical outcomes don’t match “reassuring” lab results.
III. Why AIP Is So Easy to Calculate—but Hard to Ignore
One of the most appealing features of the Atherogenic Index of Plasma is its simplicity. AIP does not require advanced lipid testing, genetic panels, or specialized imaging. It relies entirely on two numbers already present on a standard lipid panel—triglycerides and HDL cholesterol. These tests are inexpensive, widely available, and routinely ordered in primary care.
Yet what makes AIP powerful is not how hard it is to obtain, but what it reveals once calculated.
Triglycerides tend to rise when the body struggles to manage energy efficiently, especially after meals rich in refined carbohydrates or sugars. HDL cholesterol, on the other hand, often falls in states of insulin resistance, chronic inflammation, physical inactivity, and excess visceral fat. When these two patterns occur together, they signal a metabolic environment that favors small, dense, atherogenic lipoproteins and vascular injury.
AIP combines these opposing signals into a single index that amplifies risk patterns that are easy to overlook when triglycerides and HDL are viewed separately. A triglyceride level that seems only “mildly elevated” or an HDL that is “borderline low” may not raise alarms on its own—but together, they can produce an AIP value that tells a very different story.
Another reason AIP is hard to ignore is its practical flexibility. It can be used:
- With routine fasting lipid panels
- With non-fasting lipid tests
- For a one-time risk assessment
- Or for longitudinal tracking as lifestyle changes are implemented
Because AIP responds relatively quickly to changes in diet, physical activity, weight distribution, and insulin sensitivity, it becomes a useful feedback marker, not just a static risk label.
In short, AIP is easy to calculate because the data are already there. It is hard to ignore because it often reveals hidden cardiometabolic stress long before traditional markers cross diagnostic thresholds. This combination—simplicity paired with early insight—is exactly what makes AIP so useful for both clinicians and motivated individuals monitoring their own health.
Now that you understand what AIP reflects and why it’s so useful, the next step is simple—calculate your own AIP and see where you stand.
Atherogenic Index (AIP) Calculator
Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.
IV. 15 Conditions Where AIP Predicts Risk (Grouped for Clarity)
Research over the past decade shows that an elevated Atherogenic Index of Plasma is linked to a wide range of diseases—not because AIP causes them, but because it reflects shared upstream mechanisms like insulin resistance, atherogenic lipoprotein patterns, chronic inflammation, and vascular stress. For clarity, these conditions are grouped by organ system and pathophysiology.
A. Cardiovascular & Atherosclerotic Disease
1. Coronary Artery Disease (CAD)
AIP correlates with small dense LDL particles and lipid-rich plaques, helping explain why coronary disease can develop even when LDL-C appears normal.
2. Stroke Risk
Elevated AIP has been linked to ischemic stroke, likely through endothelial dysfunction, arterial stiffness, and atherosclerosis of cerebral vessels.
3. Peripheral Arterial Disease (PAD)
Because PAD reflects systemic atherosclerosis, it tracks closely with AIP, which captures diffuse vascular risk rather than single-vessel disease.
4. Aortic Calcification
Higher AIP is associated with arterial aging and calcification, reflecting long-term lipid-driven vascular injury and stiffness.
5. Plaque Vulnerability
Beyond plaque burden, AIP relates to plaque composition—particularly lipid-rich, rupture-prone plaques that lead to acute events.
B. Metabolic Dysfunction & the Diabetes Continuum
6. Insulin Resistance
AIP rises early in insulin-resistant states, often before fasting glucose or A1C become abnormal.
7. Prediabetes Development
Several studies show AIP predicting progression from normoglycemia to prediabetes, highlighting its value as an early metabolic warning sign.
8. Incident Hypertension
Insulin resistance, endothelial dysfunction, and arterial stiffness—processes reflected by AIP—also drive rising blood pressure over time.
9. Cardiometabolic Risk Clustering
AIP correlates with the clustering of waist circumference, dyslipidemia, impaired glucose regulation, and elevated blood pressure.
C. Kidney & Microvascular Disease
10. Chronic Kidney Disease (CKD)
Even early kidney dysfunction is associated with atherogenic lipid changes, making AIP a useful marker before creatinine significantly rises.
11. Diabetic Retinopathy
Microvascular injury in the retina parallels similar damage elsewhere in the body, with AIP reflecting the lipid toxicity contributing to capillary stress.
12. Cardiorenal Syndrome
AIP aligns with the interconnected dysfunction of the heart, kidneys, and metabolic system, acting as a shared upstream signal.
D. Inflammation, Uric Acid & Systemic Stress
13. Chronic Inflammation and Hyperuricemia
Higher AIP is linked with inflammatory markers and elevated uric acid, both common features of insulin-resistant states.
14. In-Hospital Mortality in Sepsis
In acute illness, AIP appears to reflect metabolic reserve and lipid transport capacity, which may influence outcomes during systemic stress.
E. Brain & Mental Health
15. Cognitive Impairment and Depression
Emerging research links elevated AIP with cognitive decline and depressive symptoms, possibly through shared mechanisms involving insulin resistance, vascular health, and brain energy metabolism.
Taken together, these associations explain why AIP behaves less like a narrow lipid ratio and more like a global cardiometabolic risk indicator. Its strength lies in revealing common upstream disturbances that manifest as disease across multiple organ systems—often long before traditional markers trigger concern.
VI. How to Use the AIP Calculator in Real Life
Once you understand what the Atherogenic Index of Plasma reflects, the next question is practical: how do you actually use it? This is where AIP becomes especially useful—not as a one-time lab curiosity, but as a real-world tracking and decision-support tool.
Step 1: Calculate Your AIP
Using your triglyceride and HDL values from a standard lipid panel, the calculator generates a single number that summarizes your atherogenic risk pattern.
Most studies categorize AIP roughly as:
- Low risk: AIP < 0.11
- Intermediate risk: AIP 0.11–0.21
- High risk: AIP > 0.21
These ranges are not disease-specific cutoffs, but risk strata that reflect increasing degrees of metabolic and vascular stress.
Do the Same AIP Values Apply to All the Conditions Listed Above?
Yes—with an important clarification.
The same AIP categories (low, intermediate, high) are generally used across the conditions discussed in this article—cardiovascular disease, stroke, CKD, insulin resistance, cognitive impairment, inflammation, and others. That’s because AIP is not diagnosing a specific disease; it is reflecting shared upstream mechanisms, including:
- Insulin resistance
- Atherogenic lipoprotein patterns
- Chronic low-grade inflammation
- Endothelial and microvascular stress
What differs is how strongly AIP predicts risk in each condition, not the direction of the risk. A higher AIP consistently signals greater vulnerability, whether the outcome is coronary disease, prediabetes, kidney dysfunction, or cognitive decline.
In other words, one index—many signals.
Step 2: Use AIP as a Trend, Not a Label
AIP is most powerful when:
- Tracked over time
- Interpreted alongside lifestyle changes
- Used to explain why risk may exist despite “normal” labs
Because triglycerides and HDL respond relatively quickly to changes in:
- Diet quality (especially sugar and refined carbs)
- Physical activity and muscle mass
- Weight distribution (visceral vs subcutaneous fat)
- Insulin sensitivity
AIP can improve—or worsen—within weeks to months. This makes it ideal for monitoring the impact of lifestyle interventions rather than waiting years for hard outcomes.
Step 3: Use AIP to Ask Better Questions
An elevated AIP should prompt questions like:
- Is insulin resistance developing even if glucose is normal?
- Is postprandial metabolism being overlooked?
- Is “normal LDL” masking a more atherogenic particle profile?
Used this way, the AIP calculator becomes a conversation starter, a motivator, and a feedback tool, rather than a standalone verdict.
VII. Why AIP Often Detects Risk Earlier Than LDL Alone
LDL cholesterol has long been the centerpiece of cardiovascular risk assessment. While useful, LDL-C measures how much cholesterol is being carried, not how it is being carried. This distinction matters.
AIP captures information that LDL-C often misses.
LDL Quantity vs Lipoprotein Quality
Two people can have the same LDL-C level, yet very different risk profiles. One may carry cholesterol in larger, buoyant particles, while the other carries it in small, dense LDL particles—which are:
- More likely to penetrate the arterial wall
- More prone to oxidation
- More strongly linked to plaque formation
AIP correlates closely with this atherogenic particle pattern, even without direct particle testing.
Earlier Signal of Metabolic Dysfunction
LDL-C often rises late in the disease process. In contrast:
- Triglycerides rise early with insulin resistance
- HDL falls early with inflammation and inactivity
By combining these two early movers, AIP frequently becomes abnormal years before LDL-C crosses treatment thresholds.
Why “Normal Cholesterol” Can Be Misleading
Many individuals who later develop:
- Coronary artery disease
- Stroke
- Type 2 diabetes
- Chronic kidney disease
were previously told their cholesterol was “fine.” AIP helps explain this disconnect by revealing hidden cardiometabolic stress that LDL alone does not capture.
AIP as an Early Warning System
Rather than replacing LDL, AIP complements it. LDL remains useful for therapy decisions, but AIP often answers a different question:
Is the metabolic environment already pushing the body toward disease—even if traditional numbers look acceptable?
That ability to detect risk earlier, cheaper, and with existing lab data is what makes AIP such a valuable addition to modern preventive care.
VII. What Naturally Lowers AIP (And Why It Works Physiologically)
At its core, the Atherogenic Index of Plasma improves when the metabolic environment becomes less atherogenic. Because AIP integrates triglycerides and HDL cholesterol, lowering it requires addressing the upstream drivers that raise triglycerides and suppress HDL—namely excess carbohydrate load, insulin resistance, physical inactivity, and chronic inflammation.
1. Reducing Sugar and Refined Carbohydrates Lowers Triglycerides
Triglycerides rise primarily when the liver is forced to convert excess glucose and fructose into fat through hepatic de novo lipogenesis. This process is amplified by:
- Frequent sugar intake
- Refined starches with high glycemic load
- Fructose-rich beverages
Lowering sugar and refined carbohydrate intake reduces hepatic VLDL production, improves postprandial metabolism, and allows triglyceride levels to fall—often rapidly. Clinically, triglycerides are among the earliest lipid markers to improve when carbohydrate quality and quantity are corrected.
2. Physical Activity Raises HDL by Increasing Metabolic Demand
HDL cholesterol reflects more than dietary fat intake—it reflects energy flux through skeletal muscle. Regular movement increases:
- Lipoprotein lipase (LPL) activity
- Reverse cholesterol transport
- HDL particle remodeling and function
Both aerobic exercise and resistance training contribute, with resistance training improving HDL function even when HDL-C rises modestly. In contrast, sedentary behavior and immobilization reliably suppress HDL, independent of diet. This is why HDL often tracks habitual activity level and muscle mass rather than calorie intake alone.
3. Improving Insulin Sensitivity Aligns Both Sides of the Ratio
Insulin resistance simultaneously:
- Raises triglycerides
- Lowers HDL
By improving insulin sensitivity—through diet, movement, sleep quality, and fat redistribution—both components of AIP improve together. This dual effect explains why AIP often responds more dramatically than LDL-C to lifestyle change.
4. Reducing Chronic Inflammation Supports Favorable Lipoprotein Patterns
Low-grade inflammation alters lipoprotein metabolism by:
- Increasing triglyceride-rich lipoproteins
- Impairing HDL maturation and function
Lifestyle strategies that lower inflammation—regular exercise, improved sleep, weight reduction, and reduced postprandial glucose spikes—support a healthier AIP profile even in the absence of medication.
Important Caveats
While AIP is strongly influenced by lifestyle in most adults, there are exceptions:
- Genetic dyslipidemias
- Excess alcohol intake
- Smoking (which lowers HDL independent of activity)
- Certain medications and endocrine disorders
For this reason, AIP should be interpreted in context, not in isolation. An elevated AIP signals increased metabolic and vascular stress, but it does not specify the exact cause.
Clinician-Facing Summary
From a physiologic standpoint, triglycerides serve as a practical surrogate for excess sugar and refined-carbohydrate exposure via hepatic de novo lipogenesis, while HDL reflects habitual physical activity and metabolic demand through skeletal muscle–driven lipoprotein remodeling.
When combined into the Atherogenic Index of Plasma, these two routinely available markers integrate diet, physical activity, insulin sensitivity, and inflammation into a single, scalable risk signal.
AIP does not diagnose disease but often identifies early cardiometabolic stress before traditional lipid thresholds are exceeded, making it useful for risk stratification and lifestyle monitoring across multiple conditions.
VIII. Key Takeaway: AIP as a Modern, Practical Risk Marker
The Atherogenic Index of Plasma deserves attention because it sits at the intersection of lipids, glucose metabolism, physical activity, and vascular health. Like blood pressure and fasting glucose, AIP reflects the body’s response to everyday exposures—what we eat, how often we move, and how efficiently we handle energy.
While it does not replace traditional markers, it adds context that those markers often miss, especially in the early stages of disease development.
AIP is particularly valuable for people whose standard lab results appear “normal,” yet who carry hidden cardiometabolic risk. Individuals with normal LDL cholesterol, borderline triglycerides, or only mildly reduced HDL may be falsely reassured by routine reports.
In these cases, AIP can reveal an unfavorable metabolic pattern long before overt diabetes, hypertension, atherosclerosis, or kidney disease becomes clinically apparent. This makes it relevant not only for high-risk patients but also for those who want early insight rather than late diagnosis.
One of AIP’s greatest strengths is its simplicity. It relies on numbers already measured in routine care, requires no additional testing, and responds meaningfully to lifestyle change.
In an era of increasingly complex biomarkers and expensive panels, AIP reminds us that useful clinical insight does not always require complexity.
When interpreted thoughtfully and tracked over time, this simple ratio can function as an accessible, scalable signal of cardiometabolic health—bridging the gap between laboratory data and real-world risk.
The associations described above are based on observational and mechanistic studies. AIP is a risk marker and monitoring tool, not a diagnostic test or a substitute for clinical evaluation.
It is also likely that more than 15 conditions are influenced or predicted by the Atherogenic Index of Plasma; the ones discussed here represent the most commonly reported and clinically relevant associations, and AIP can be used in combination with other metabolic and cardiovascular markers to provide a more complete picture of overall risk.
Note on Future Articles:
Many of the conditions linked to the Atherogenic Index of Plasma were only briefly introduced here. In upcoming articles, each group—cardiovascular disease, metabolic dysfunction, kidney and microvascular disease, brain health, and systemic illness—will be explored in greater depth, with a closer look at the physiology, clinical evidence, and practical implications of AIP in each setting.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- Atherogenic Index (AIP): Meaning, Clinical Uses and Calculator
- Small Dense LDL: What It Means And How To Improve It
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- LDL Particle Number Explained: A Better Marker Than LDL Cholesterol
- TG/HDL Ratio Explained: What It Means and How to Improve It
- HDL Function Explained: Good vs Bad HDL
- High Triglycerides: Causes, Dangers, And How To Lower
- Metabolic Health Check: Your Metabolic Digest (What It Means + How to Improve It)
- New Science Debunks the Dangers of Saturated Fats on Heart Disease
- Machine Learning Finds Your Hidden Heart Disease Risks
- ApoB Reveals Hidden Heart Disease And Diabetes Risk Early
- How to Interpret ApoB and ApoA1 Results
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- CAC And CTA Scans Help Detect Heart Disease Early
- ApoB and ApoA1 Best Predict Heart Attack: How To Get Tested
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- Heart Attack Risk? Use The Framingham Risk Calculator And Lower It Now!
- Discover Your Cardiac Age with This Free Calculator
- Heart Rate Recovery Reveals Hidden Secrets About Your Heart
- Drink Coffee At This Time To Slash Heart Attack Risk
- The FODMAP Trap That Mimics Heart Attacks During Exercise
- The Hidden Link Between High Blood Sugar and Heart Attacks
- Strep From the Mouth and Blood and Sudden Cardiac Death — What You Need to Know
- Lithium’s Hidden Power: Unlocking Protection Against Cardiovascular Disease
- How Reduced Blood Sugar Lowers BP And Cardiovascular Risks
- Cholesterol and Blood Sugar: The Strong Link
References:
- Zhai L, Huo RR, Zuo YL. Atherogenic index of plasma and obesity-related risk of stroke in middle-aged and older Chinese adults: a national prospective cohort study. Diabetol Metab Syndr. 2024 Oct 8;16(1):245. doi: 10.1186/s13098-024-01481-y. PMID: 39380102; PMCID: PMC11462917. https://pubmed.ncbi.nlm.nih.gov/39380102/
- Xu C, Xu S, Mai P, Tang J, Xu J, Zhang H. Association between the atherogenic index of plasma and abdominal aortic calcification in adults: a cross-sectional study. BMC Public Health. 2024 Sep 6;24(1):2431. doi: 10.1186/s12889-024-19862-3. PMID: 39243068; PMCID: PMC11380399. https://pubmed.ncbi.nlm.nih.gov/39243068/
- Hohneck A, Weingärtner O. Atherogenic index of plasma – a new frontier in predicting peripheral arterial disease risk? Vasa. 2025 May;54(3):151-153. doi: 10.1024/0301-1526/a001157. PMID: 40321097. https://pubmed.ncbi.nlm.nih.gov/40321097/
- Qu L, Fang S, Lan Z, Xu S, Jiang J, Pan Y, Xu Y, Zhu X, Jin J. Association between atherogenic index of plasma and new-onset stroke in individuals with different glucose metabolism status: insights from CHARLS. Cardiovasc Diabetol. 2024 Jun 21;23(1):215. doi: 10.1186/s12933-024-02314-y. PMID: 38907337; PMCID: PMC11193183. https://pubmed.ncbi.nlm.nih.gov/38907337/
- Wu S, Gao Y, Liu W, Wang R, Ma Q, Sun J, Han W, Jia S, Du Y, Zhao Z, Liu Y, Wang Z, Zhou Y. The relationship between atherogenic index of plasma and plaque vulnerabilities: an optical coherence tomography study. Cardiovasc Diabetol. 2024 Dec 18;23(1):442. doi: 10.1186/s12933-024-02532-4. PMID: 39696478; PMCID: PMC11656644. https://pubmed.ncbi.nlm.nih.gov/39696478/
- Zou Y, Lu S, Li D, Huang X, Wang C, Xie G, Duan L, Yang H. Exposure of cumulative atherogenic index of plasma and the development of prediabetes in middle-aged and elderly individuals: evidence from the CHARLS cohort study. Cardiovasc Diabetol. 2024 Sep 30;23(1):355. doi: 10.1186/s12933-024-02449-y. PMID: 39350154; PMCID: PMC11443941. https://pubmed.ncbi.nlm.nih.gov/39350154/
- Huang J, Chen C, Jie C, Li R, Chen C. L-shaped relationship between atherogenic index of plasma with uric acid levels and hyperuricemia risk. Front Endocrinol (Lausanne). 2024 Dec 9;15:1461599. doi: 10.3389/fendo.2024.1461599. PMID: 39717100; PMCID: PMC11663671. https://pubmed.ncbi.nlm.nih.gov/39717100/
- Chen GL, Chen GX, Wan WT. Association between atherogenic index of plasma and depression risk: a meta-analysis. Front Psychiatry. 2025 Nov 19;16:1665118. doi: 10.3389/fpsyt.2025.1665118. PMID: 41346637; PMCID: PMC12673221. https://pubmed.ncbi.nlm.nih.gov/41346637/
- Zhou J, Han H, Bai W. Association between atherogenic index of plasma and cognitive impairment in middle-aged and older adults: results from CHARLS. Front Aging Neurosci. 2025 Feb 26;17:1506973. doi: 10.3389/fnagi.2025.1506973. PMID: 40078639; PMCID: PMC11897900. https://pubmed.ncbi.nlm.nih.gov/40078639/
- Shi C, He C, Qin L, Bai W. Association between atherogenic index of plasma and depression in individuals with different glucose metabolism status. Front Psychiatry. 2025 Jun 3;16:1530940. doi: 10.3389/fpsyt.2025.1530940. PMID: 40530050; PMCID: PMC12170628. https://pubmed.ncbi.nlm.nih.gov/40530050/
- Xu S, Hu J, Ouyang Z, Yuan M, Zheng Y, Liu X, Shen Y. Elevated atherogenic index of plasma is associated with increased cardiorenal syndrome prevalence: a cross-sectional study. Ren Fail. 2025 Dec;47(1):2472037. doi: 10.1080/0886022X.2025.2472037. Epub 2025 Mar 2. PMID: 40025821; PMCID: PMC11878164. https://pubmed.ncbi.nlm.nih.gov/40025821/
- Wang Z, Lu B, Zhang L, Tang F, Pan Y, Zhong S. Association between the atherogenic index of plasma and kidney stones: a nationally representative study. BMC Urol. 2024 Aug 24;24(1):179. doi: 10.1186/s12894-024-01567-9. PMID: 39182034; PMCID: PMC11344440. https://pubmed.ncbi.nlm.nih.gov/39182034/
- Zeng H, Ma C, Zheng R, Jiang C, Zhong Y, Qian S, Shi Y. Association of the atherogenic index of plasma with in-hospital mortality in patients with sepsis-induced coagulopathy. Lipids Health Dis. 2025 Dec 1;25(1):7. doi: 10.1186/s12944-025-02817-x. PMID: 41327338; PMCID: PMC12777205. https://pubmed.ncbi.nlm.nih.gov/41327338/
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.